Alnylam Pharmaceuticals (ALNY) Other financing activities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Other financing activities data on file, last reported at $33.6 million in Q2 2026.

• Quarterly Other financing activities fell 58.68% year-over-year to $33.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $166.2 million (down 39.56% YoY) and the FY2025 annual result came in at $250.0 million, down 17.47% from the prior year.
• Other financing activities advanced to $33.6 million in Q2 2026, from $13.2 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $153.0 million in Q3 2022 to a low of $13.2 million in Q1 2026.
• A 5-year average of $55.9 million and a median of $42.0 million in 2023 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2023 — Other financing activities plunged 83.79% — and 2024, when it jumped 335.54%.
• Tracing ALNY's Other financing activities over 5 years: stood at $56.7 million in 2022, then plunged by 45.53% to $30.9 million in 2023, then grew by 17.43% to $36.3 million in 2024, then increased by 14.95% to $41.7 million in 2025, then retreated by 19.52% to $33.6 million in 2026.
• The last three Other financing activities figures came in at $33.6 million (Q2 2026), $13.2 million (Q1 2026), and $41.7 million (Q4 2025), per Business Quant data.